About editas medicine inc. - EDIT
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.
EDIT At a Glance
Editas Medicine, Inc.
11 Hurley Street
Cambridge, Massachusetts 02141
| Phone | 1-617-401-9000 | Revenue | 40.52M | |
| Industry | Biotechnology | Net Income | -160,060,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 25.395% | |
| Fiscal Year-end | 12 / 2026 | Employees | 87 | |
| View SEC Filings |
EDIT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.49 |
| Price to Book Ratio | 7.352 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.191 |
| Enterprise Value to Sales | 2.764 |
| Total Debt to Enterprise Value | 0.685 |
EDIT Efficiency
| Revenue/Employee | 465,747.126 |
| Income Per Employee | -1,839,770.115 |
| Receivables Turnover | 2.67 |
| Total Asset Turnover | 0.153 |
EDIT Liquidity
| Current Ratio | 3.544 |
| Quick Ratio | 3.544 |
| Cash Ratio | 3.171 |
EDIT Profitability
| Gross Margin | 86.977 |
| Operating Margin | -245.153 |
| Pretax Margin | -395.015 |
| Net Margin | -395.015 |
| Return on Assets | -60.615 |
| Return on Equity | -198.141 |
| Return on Total Capital | -153.911 |
| Return on Invested Capital | -129.28 |
EDIT Capital Structure
| Total Debt to Total Equity | 281.102 |
| Total Debt to Total Capital | 73.76 |
| Total Debt to Total Assets | 41.122 |
| Long-Term Debt to Equity | 240.677 |
| Long-Term Debt to Total Capital | 63.153 |